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Using the mini-mental state examination (MMSE) we classiﬁed patients as mild 
(27–20), moderate (19–10) or severe (<10). We calculated the association between 
previous and current MMSE stage and the association between previous MMSE stage 
and institutionalization using multinomial logistic models with random effects to 
account for individual and center level correlation, controlling for demographic char-
acteristics and time since last observation. The coefﬁcients from the regressions were 
used to calculate predicted probabilities using the population means for each of the 
covariates. RESULTS: Our analysis was limited to 3,418 patients with dementia 
(52.3% probable AD) and two or more observations with complete data for our 
covariates of interest. Average baseline age was 76.72 years old. Average MMSE was 
17.05. The majority were female, 50.4%. The regression coefﬁcient for the previous 
MMSE stage was signiﬁcant in all cases and suggests that being in a higher MMSE 
stage at the previous visit is associated with being in a higher MMSE stage or dead. 
Previous MMSE stage was found to be strongly associated with institutionalization. 
White, non-Hispanic, unmarried patients were more likely to be institutionalized, all 
else equal. Patients with non-AD dementia were more likely to be institutionalized 
than patients with AD. CONCLUSIONS: Patients with AD in the NACC -UDS 
database transition more quickly to more severe stages of MMSE than non-AD 
dementia patients. Non-AD dementia patients are more likely to transition to institu-
tionalization and die than patients with AD.
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OBJECTIVES: The purpose of this analysis was to estimate the impact of escitalopram 
(generic drug) reimbursement on the budget of the National Health Fund (NHF) in 
Poland. METHODS: The budget impact analysis was prepared for 5 years time 
horizon (2009–2013) from the public payer’s as well as patient’s perspective. Two 
scenarios were compared: present—without reimbursement of generic version of esci-
talopram and proposed—placing of escitalopram on the list of reimbursed drugs in 
Poland. It was assumed that escitalopram will take over a part of market of selective 
serotonin reuptake inhibitors (SSRIs) and selective serotonin-noradrenergic reuptake 
inhibitors (SNRIs). The analysis was performed in two variants: basic analysis, assum-
ing new reimbursement limit for escitalopram which equals the retail price of generic 
escitalopram and alternative variant presuming equal reimbursement limits for esci-
talopram and venlafaxine. Additionally, the minimum and maximum case scenarios 
and one-way sensitivity analyses were performed. RESULTS: Assuming the reimburse-
ment of generic escitalopram in basic variant, the annual expenses from the budget 
of the NHF for major depressive disorder treatment would rise from 344,723 PLN in 
ﬁrst year to 5,770,153 PLN in ﬁfth year in comparison to present scenario. In alterna-
tive variant, the estimated expenses would rise from 144,833 PLN in ﬁrst year to 
2,716,183 PLN in ﬁfth year. From patient’s perspective the expenses for MDD treat-
ment would decrease in basic variant from 245,874 PLN to 4,829,704 PLN and in 
alternative variant from 45,984 PLN to 1,775,734 PLN in ﬁrst and ﬁfth year, respec-
tively, in comparison to present scenario. CONCLUSIONS: Budget impact analysis 
showed that the reimbursement of generic escitalopram would increase expenses from 
the NHF’s perspective and savings from patient’s perspective.
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OBJECTIVES: Bipolar disorder (BPD) is a debilitating recurrent chronic mental 
illness, characterized by cycling states of depression, mania, hypomania, and mixed 
episodes. The objectives of this study were to calculate national estimates of the annual 
burden of inpatient hospitalizations of children and adolescents with bipolar disorder 
(BPD); to describe and compare the burden across various patient characteristics, 
hospital characteristics, and key comorbidities associated with BPD; and to determine 
the independent effects of these factors on hospitalization costs. METHODS: Dis-
charge observations for children whose primary diagnosis was BPD were collected 
from the Kids’ Inpatient Database (KID). The burden was estimated as total number 
of days in the hospital, total charges, and total costs. Mean costs and charges were 
calculated and were broken down by patient and hospital characteristics and by the 
top six comorbidities found for BPD. Ordinary–least-squares regression models 
explaining cost were estimated for both 2003 and 2006, and the models were com-
pared by way of a Chow test. RESULTS: There were 39,136 (40,679) bipolar disorder 
discharges in 2003 (2006), with total associated costs of $176 ($233) million in 2003 
(2006). The mean cost was $4,490 ($5,725), while the mean length of stay was 8.12 
(8.99) days in 2003 (2006). Factors associated with higher cost included youth 
(younger than 13), being black, being from a high-income family, having many diag-
noses, being insured by Medicaid, living in the North East or West regions of the 
country, and having a long hospital stay. CONCLUSIONS: Declining trends in mean 
cost and length of stay, documented in previous studies for children with BPD, per-
sisted into 2003 but showed a slight reversal by 2006.
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OBJECTIVES: There is accumulating evidence of sub-therapeutic dosing of second-
generation antipsychotics (SGAs), leading to suboptimal control of disease and higher 
overall treatment costs. Additional evidence is needed to better understand the clinical 
and economic outcomes of patients who receive clinically effective doses of SGAs. The 
objectives of this study were to distinguish patients receiving clinically recommended 
doses of SGAs and compare their medical care costs. METHODS: Patients with 
schizophrenia (N = 12,133) on an oral SGA (aripiprazole, olanzapine, quetiapine, 
risperidone or ziprasidone) were identiﬁed in Medicaid claims databases (2001–2008) 
from 8 states. Patients were followed for 18 months (6 month pre-index period during 
which patients did not receive an SGA, followed by a 12-month post-index utilization 
period to determine total costs). For patients on recommended dosing, costs were 
compared using a generalized linear model with a gamma distribution and log-link 
function, adjusting for baseline covariates (age, gender, race, pre-index costs, Charlson 
co-morbidity score, and speciﬁc psychiatric co-morbidities) with ziprasidone as the 
reference group. RESULTS: Of the 12,133 patients meeting study criteria 7,213 (59%) 
were taking clinically recommended doses by day 61 of their follow-up period. Patients 
on quetiapine had the lowest percentage at 37% (N = 1,057/2,869). Other results 
were aripiprazole 66%(N = 996/1515), olanzapine 65% (N = 1831/2828), risperidone 
73% (N = 2807/3821), and ziprasidone, 47% (N = 522/1,100). When comparing 
groups of patients with recommended dosing, mental health-related costs (p = 0.006) 
and all-cause costs (p = 0.0005) were statistically higher for the quetiapine group 
compared to the ziprasidone group. CONCLUSIONS: Less than two-thirds of the 
Medicaid patients with schizophrenia who were started on an SGA were taking clini-
cally recommended doses 2 months after their initial start. For patients using clinically 
recommended doses, those taking quetiapine had higher mental health-related costs 
and higher all-cause costs compared to patients taking ziprasidone.
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OBJECTIVES: To compare the risk of hospitalization and associated inpatient psy-
chiatric treatment costs among patients with bipolar disorder treated with aripipra-
zole, ziprasidone, olanzapine, quetiapine or risperidone. METHODS: A retrospective 
cohort study using the Pharmetrics Patient-Centric database from January 1, 2003 
-September 30, 2008 was conducted. Included patients were aged 18–64 years, diag-
nosed with bipolar disorder, and newly treated with atypical antipsychotic medica-
tions. Patients were followed from treatment initiation to psychiatric hospitalization, 
medical hospitalization, discontinuation of index medication, loss to follow-up, or 
one year. Mean length of therapy was similar among the treatment groups. General-
ized gamma regression compared inpatient costs between the groups. RESULTS: 
Among 19,176 bipolar patients, those treated with aripiprazole (n = 3,690) had a 
lower risk of hospitalization during their time on treatment (4.9%) compared to 
patients receiving ziprasidone (9.2% p < 0.001, n = 1515)), olanzapine (7.0% p < 
0.001, n = 3038)), quetiapine (7.3% p < 0.001, n = 7936), and risperidone (7.2% p 
< 0.001, n = 2997). Fewer hospitalizations translated into lower per-patient-per-
month psychiatric-related inpatient health care costs for patients receiving aripipra-
zole ($121) compared to those receiving other atypical antipsychotics (ziprasidone 
$249 p < 0.001, olanzapine ($203 p < 0.001), and quetiapine ($182 p < 0.006). Dif-
ferences in hospitalization costs were not statistically signiﬁcant between aripiprazole 
and risperidone ($159 p < 0.354). Total psychiatric-related health care costs were also 
signiﬁcantly lower among aripiprazole patients than patients in each of the other 
treatment groups (p < 0.05). CONCLUSIONS: Among patients with bipolar disorder 
and newly treated with atypical antipsychotic medications, treatment with aripipra-
zole was associated with a lower risk of psychiatric hospitalization compared to 
patients receiving other atypical antipsychotic medications and lower psychiatric-
related inpatient costs compared to patients receiving ziprasidone, quetiapine, or 
olanzapine. These data are consistent with previous published ﬁndings studying the 
Ingenix integrated claims dataset. The results of this study suggest that aripiprazole 
may offer an economic advantage over other atypical antipsychotic medications in 
this patient population.
